<p>在過去的 7 天裏，美國市場保持平穩，儘管過去一年上漲了 29%，預計收益將以每年 16% 的速度增長。在這種穩定增長的背景下，識別高增長的科技股需要尋找那些展現出強大創新能力和適應能力的公司，以利用這些積極的市場條件。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.37%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>21.66%</td>
<td>27.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>35.48%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.27%</td>
<td>46.38%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 66 只股票的完整列表。</p>
<p>以下是篩選器中一些選擇的預覽。</p>
<h2>AvePoint (AVPT)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> AvePoint, Inc. 提供雲原生數據管理軟件平台，覆蓋北美、歐洲、中東、非洲和亞太地區，市值約為 21.6 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其軟件和編程部門產生收入，總額為 4.195 億美元。</p>
<p>AvePoint 最近的軌跡展示了其對不斷變化的科技環境的強大適應能力，財務表現顯著好轉。2025 年，該公司的收入從前一年的 3.3048 億美元增加到 4.195 億美元，同時淨收入從 2909 萬美元的淨虧損轉為 3480 萬美元的淨收入，反映出每年 32.07% 的盈利增長。這些數據得益於 AvePoint 在多個雲平台（如 Microsoft 365 和 Google Cloud）上戰略性增強的人工智能治理能力，解決了企業當前面臨的關鍵多雲合規和數據安全挑戰。這一戰略轉變不僅提升了他們的服務產品，還使他們在雲治理和數據管理的高增長領域中佔據了良好位置，抓住了對集成 AI 解決方案日益增長的需求，這些解決方案確保了運營效率和嚴格的安全協議。</p>
<ul>
<li>點擊這裏深入瞭解 AvePoint 的完整分析健康報告。</li>
<li>通過我們的歷史報告獲取 AvePoint 的過去趨勢和表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 AVPT 收益和收入增長</p>
<h2>Krystal Biotech (KRYS)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商業階段的生物技術公司，專注於發現、開發、製造和商業化針對美國高未滿足醫療需求疾病的基因藥物，市值為 79.2 億美元。</p>
<p><strong>運營：</strong> Krystal Biotech 主要通過其基因藥物部門產生收入，金額為 3.8913 億美元。該公司在生物技術領域運營，專注於解決美國重大未滿足需求的疾病。</p>
<p>Krystal Biotech 在生物技術領域脱穎而出，過去一年展現出 129.7% 的顯著盈利增長，遠超行業平均水平 50.1%。這一增長得益於強勁的收入和盈利預測，預計年增長分別為 19.8% 和 22%，超出更廣泛市場的預期。該公司對創新的承諾在其最近獲得 FDA RMAT 認證的 KB707 中得以體現，旨在治療晚期非小細胞肺癌，這證明了其在通過先進基因療法解決關鍵未滿足醫療需求方面的潛力。這一戰略重點不僅突顯了 Krystal 在開創新療法中的作用，還使其在一個快速擴張的競爭領域中佔據了有利位置。</p>
<ul>
<li>點擊這裏深入瞭解 Krystal Biotech 的複雜健康報告。</li>
<li>查看我們的歷史表現報告，以獲取 Krystal Biotech 過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 KRYS 收益和收入增長</p>
<h2>Q2 Holdings (QTWO)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Q2 Holdings, Inc. 提供針對金融機構、金融科技公司和替代金融公司的數字解決方案，市值為 30.3 億美元。</p>
<p><strong>運營：</strong> Q2 Holdings 主要通過銷售、實施和支持其數字解決方案產生收入，總額為 7.9481 億美元。該公司為美國的金融機構和金融科技公司提供技術驅動的服務。</p>
<p>Q2 Holdings 在科技行業中脱穎而出，專注於為金融服務提供基於人工智能的解決方案，最近推出的用户活動監控和限制權限模式便是其增強防欺詐保護的有力證明。這些創新是 Q2 更廣泛戰略的一部分，旨在將人工智能無縫整合到數字銀行業務中，反映出向更動態、實時的欺詐緩解技術的顯著轉變。在財務方面，Q2 展現出強勁的增長，年收益增長 34.5%，年收入增長 9.6%。這一表現得益於諸如第二季度代碼等戰略舉措，該舉措通過利用生成性人工智能加速金融機構的開發週期，從而提升平台在競爭市場中的實用性和吸引力。</p>
<ul>
<li>在這裏深入瞭解 Q2 Holdings 的詳細健康報告。</li>
<li>通過我們的詳細歷史業績報告評估 Q2 Holdings 的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 QTWO 收益和收入增長</p>
<h2>讓它發生</h2>
<ul>
<li>在這裏探索我們完整的 66 家美國高增長科技和人工智能股票陣容。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時獲取股票的關鍵更新。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，獲取各市場無與倫比的股票分析。</li>
</ul>
<h2>準備探索其他投資風格嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，分析師和管理層均持樂觀態度。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
<h3>估值複雜，但我們在這裏為您簡化。</h3>
<p>通過我們的詳細分析，發現 Q2 Holdings 是否可能被低估或高估，分析內容包括 <strong>公允價值估算、潛在風險、股息、內部交易和財務狀況。</strong></p>
<p>獲取免費分析</p>

KRYS

PLTR

AVPT

<p>美國市場在過去一年中增長了 29%，預計年收益將增長 16%。主要的高增長科技股票包括 Marker Therapeutics、Palantir Technologies 和 Krystal Biotech，顯示出顯著的收入和收益增長。AvePoint、Krystal Biotech 和 Q2 Holdings 因其創新的方法和強勁的財務表現而受到關注，每家公司都在適應市場需求，專注於人工智能和數字解決方案。整體趨勢表明，美國的科技投資環境強勁</p>

<p>Over the last 7 days, the United States market has remained flat, although it is up 29% over the past year with earnings forecast to grow by 16% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive market conditions.</p>
<div class="lb-trans"><p>在過去的 7 天裏，美國市場保持平穩，儘管過去一年上漲了 29%，預計收益將以每年 16% 的速度增長。在這種穩定增長的背景下，識別高增長的科技股需要尋找那些展現出強大創新能力和適應能力的公司，以利用這些積極的市場條件。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.37%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>21.66%</td>
<td>27.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>35.48%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.27%</td>
<td>46.38%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.37%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>21.66%</td>
<td>27.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>35.48%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.27%</td>
<td>46.38%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 66 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器中的 66 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是篩選器中一些選擇的預覽。</p>
</div><h2>AvePoint (AVPT)</h2>
<div class="lb-trans"><h2>AvePoint (AVPT)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> AvePoint, Inc. offers a cloud-native data management software platform across various regions including North America, Europe, the Middle East, Africa, and the Asia Pacific with a market capitalization of approximately $2.16 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> AvePoint, Inc. 提供雲原生數據管理軟件平台，覆蓋北美、歐洲、中東、非洲和亞太地區，市值約為 21.6 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its software and programming segment, totaling $419.50 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其軟件和編程部門產生收入，總額為 4.195 億美元。</p>
</div><p>AvePoint's recent trajectory illustrates a robust adaptation to the evolving tech landscape, underscored by a significant turnaround in financial performance. In 2025, the company reported a revenue increase to $419.5 million from $330.48 million the previous year, alongside an impressive swing to a net income of $34.8 million from a net loss of $29.09 million, reflecting an earnings growth of 32.07% per year. These figures are complemented by AvePoint's strategic enhancements in AI governance capabilities across multiple cloud platforms such as Microsoft 365 and Google Cloud, addressing critical multicloud compliance and data security challenges faced by enterprises today. This strategic pivot not only boosts their service offerings but also positions them well within the high-growth sectors of cloud governance and data management, tapping into escalating demands for integrated AI solutions that ensure both operational efficiency and stringent security protocols.</p>
<div class="lb-trans"><p>AvePoint 最近的軌跡展示了其對不斷變化的科技環境的強大適應能力，財務表現顯著好轉。2025 年，該公司的收入從前一年的 3.3048 億美元增加到 4.195 億美元，同時淨收入從 2909 萬美元的淨虧損轉為 3480 萬美元的淨收入，反映出每年 32.07% 的盈利增長。這些數據得益於 AvePoint 在多個雲平台（如 Microsoft 365 和 Google Cloud）上戰略性增強的人工智能治理能力，解決了企業當前面臨的關鍵多雲合規和數據安全挑戰。這一戰略轉變不僅提升了他們的服務產品，還使他們在雲治理和數據管理的高增長領域中佔據了良好位置，抓住了對集成 AI 解決方案日益增長的需求，這些解決方案確保了運營效率和嚴格的安全協議。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of AvePoint.</li>
<li>Gain insights into AvePoint's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 AvePoint 的完整分析健康報告。</li>
<li>通過我們的歷史報告獲取 AvePoint 的過去趨勢和表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth"/></p>
<p>AVPT Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 AVPT 收益和收入增長</p>
</div><h2>Krystal Biotech (KRYS)</h2>
<div class="lb-trans"><h2>Krystal Biotech (KRYS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $7.92 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商業階段的生物技術公司，專注於發現、開發、製造和商業化針對美國高未滿足醫療需求疾病的基因藥物，市值為 79.2 億美元。</p>
</div><p><strong>Operations:</strong> Krystal Biotech generates revenue primarily from its genetic medicines segment, which amounted to $389.13 million. The company operates within the biotechnology sector, focusing on addressing diseases with significant unmet needs in the U.S.</p>
<div class="lb-trans"><p><strong>運營：</strong> Krystal Biotech 主要通過其基因藥物部門產生收入，金額為 3.8913 億美元。該公司在生物技術領域運營，專注於解決美國重大未滿足需求的疾病。</p>
</div><p>Krystal Biotech stands out in the biotechnology landscape, showcasing a remarkable earnings growth of 129.7% over the past year, significantly outpacing the industry's average of 50.1%. This growth is underpinned by robust revenue and earnings forecasts, with expected annual increases of 19.8% and 22%, respectively, which eclipse broader market projections. The firm's commitment to innovation is evident in its recent FDA RMAT designation for KB707, aimed at treating advanced NSCLC—a testament to its potential in addressing critical unmet medical needs through advanced gene therapies. This strategic focus not only highlights Krystal’s role in pioneering new treatments but also positions it favorably within a competitive sector poised for rapid expansion.</p>
<div class="lb-trans"><p>Krystal Biotech 在生物技術領域脱穎而出，過去一年展現出 129.7% 的顯著盈利增長，遠超行業平均水平 50.1%。這一增長得益於強勁的收入和盈利預測，預計年增長分別為 19.8% 和 22%，超出更廣泛市場的預期。該公司對創新的承諾在其最近獲得 FDA RMAT 認證的 KB707 中得以體現，旨在治療晚期非小細胞肺癌，這證明了其在通過先進基因療法解決關鍵未滿足醫療需求方面的潛力。這一戰略重點不僅突顯了 Krystal 在開創新療法中的作用，還使其在一個快速擴張的競爭領域中佔據了有利位置。</p>
</div><ul>
<li>Navigate through the intricacies of Krystal Biotech with our comprehensive health report here.</li>
<li>Review our historical performance report to gain insights into Krystal Biotech's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Krystal Biotech 的複雜健康報告。</li>
<li>查看我們的歷史表現報告，以獲取 Krystal Biotech 過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>KRYS Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 KRYS 收益和收入增長</p>
</div><h2>Q2 Holdings (QTWO)</h2>
<div class="lb-trans"><h2>Q2 Holdings (QTWO)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Q2 Holdings, Inc. offers digital solutions tailored for financial institutions, FinTechs, and alternative finance companies across the United States, with a market capitalization of $3.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Q2 Holdings, Inc. 提供針對金融機構、金融科技公司和替代金融公司的數字解決方案，市值為 30.3 億美元。</p>
</div><p><strong>Operations:</strong> Q2 Holdings generates revenue primarily through the sale, implementation, and support of its digital solutions, amounting to $794.81 million. The company caters to financial institutions and FinTechs in the U.S., focusing on providing technology-driven services.</p>
<div class="lb-trans"><p><strong>運營：</strong> Q2 Holdings 主要通過銷售、實施和支持其數字解決方案產生收入，總額為 7.9481 億美元。該公司為美國的金融機構和金融科技公司提供技術驅動的服務。</p>
</div><p>Q2 Holdings is distinguishing itself in the tech sector with a strong focus on AI-driven solutions for financial services, evidenced by its recent unveiling of User Activity Monitoring and Restricted Entitlements Mode to enhance fraud protection. These innovations are part of Q2's broader strategy to integrate AI seamlessly within digital banking operations, reflecting a significant shift towards more dynamic, real-time fraud mitigation techniques. Financially, Q2 has demonstrated robust growth with a 34.5% annual increase in earnings and an impressive 9.6% rise in revenue year-over-year. This performance is underpinned by strategic initiatives like Second Quarter Code, which accelerates development cycles within financial institutions by leveraging generative AI, thereby enhancing the platform's utility and attractiveness in a competitive market.</p>
<div class="lb-trans"><p>Q2 Holdings 在科技行業中脱穎而出，專注於為金融服務提供基於人工智能的解決方案，最近推出的用户活動監控和限制權限模式便是其增強防欺詐保護的有力證明。這些創新是 Q2 更廣泛戰略的一部分，旨在將人工智能無縫整合到數字銀行業務中，反映出向更動態、實時的欺詐緩解技術的顯著轉變。在財務方面，Q2 展現出強勁的增長，年收益增長 34.5%，年收入增長 9.6%。這一表現得益於諸如第二季度代碼等戰略舉措，該舉措通過利用生成性人工智能加速金融機構的開發週期，從而提升平台在競爭市場中的實用性和吸引力。</p>
</div><ul>
<li>Dive into the specifics of Q2 Holdings here with our thorough health report.</li>
<li>Assess Q2 Holdings' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 Q2 Holdings 的詳細健康報告。</li>
<li>通過我們的詳細歷史業績報告評估 Q2 Holdings 的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth"/></p>
<p>QTWO Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 QTWO 收益和收入增長</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Investigate our full lineup of 66 US High Growth Tech and AI Stocks right here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏探索我們完整的 66 家美國高增長科技和人工智能股票陣容。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時獲取股票的關鍵更新。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，獲取各市場無與倫比的股票分析。</li>
</ul>
</div><h2>Ready To Venture Into Other Investment Styles?</h2>
<div class="lb-trans"><h2>準備探索其他投資風格嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，分析師和管理層均持樂觀態度。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值複雜，但我們在這裏為您簡化。</h3>
</div><p>Discover if Q2 Holdings might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通過我們的詳細分析，發現 Q2 Holdings 是否可能被低估或高估，分析內容包括 <strong>公允價值估算、潛在風險、股息、內部交易和財務狀況。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>獲取免費分析</p>
</div>

High Growth Tech Stocks To Watch In The US April 2026

- 美國市場過去一週保持平穩，年增幅達 29%。  
- 高增長科技公司依靠創新和適應力抓住市場機遇。  
- 文章列出多家強勁成長的科技公司及其財務表現。

2026 年 4 月美國值得關注的高增長科技股票